Virus Safety for Biotherapeutics: Testing and Clearance Strategies Following the ICH Q5A Revision
Planova S20N evaluation on PCC and IgG products
Addressing Continuous Bioprocessing Challenges From Virus Removal Perspective
New Generation Planova™ S20N Demonstrates Robust Performance for Multi-Specific Antibodies
Nanofiltration Strategies in Plasma Protein Process Development
使用Planova™ BioEX可减少开发病毒过滤工艺中的所需资源
病毒过滤工艺中使用Planova™ BioEX的生产注意事项